Amyotrophic Lateral Sclerosis (ALS) Drug Discovery Service

Creative Biolabs provides custom amyotrophic lateral sclerosis (ALS) drug discovery services for research teams developing small molecules, oligonucleotides, biologics, or other experimental therapeutic approaches. We help define a disease-relevant model, establish a measurable pathological phenotype, screen and prioritize candidates, investigate mechanism of action, and plan confirmatory preclinical studies.

The service supports genotype-focused ALS programs, studies of sporadic ALS, motor neuron protection, RNA and protein homeostasis, neuroinflammation, and neuromuscular dysfunction. Project support can combine patient-derived or engineered cellular models, motor neuron phenotypic screening, molecular and functional assays, glial or muscle co-cultures, and selected animal-model studies.

Define the ALS Research Decision

ALS drug discovery requires a clear connection between the therapeutic hypothesis and the experimental system. A study aimed at lowering mutant SOD1 should establish target modulation in a relevant genetic background. A neuroprotective program for sporadic ALS may instead need reproducible survival or axonal phenotypes across several patient-derived lines. A candidate directed at glial toxicity or neuromuscular communication requires a model that includes the cellular interaction under investigation.

• Disease context: Define the ALS genotype, sporadic donor population, or molecular pathology the program is intended to address.
• Therapeutic hypothesis: State whether the candidate should correct a causal molecular event, preserve motor neuron function, alter a supportive cell population, or improve neuromuscular output.
• Primary endpoint: Choose a measurable phenotype that is present before treatment and biologically connected to the proposed mechanism.
• Treatment objective: Separate prevention of injury, rescue after phenotype onset, and durability after treatment withdrawal.
• Development gate: Agree on the evidence needed to select a hit, compare leads, confirm a target, or justify an in vivo study.

A staged program can begin with Amyotrophic Lateral Sclerosis In Vitro Modeling Service and ALS Model based In Vitro Assay Services. These complementary routes allow model development and assay selection to be aligned rather than treating either as a fixed package.

Select ALS Models Around the Disease Mechanism

We select the genotype, cell composition, maturation state, and perturbation method around the project question. Endogenous patient-derived models can preserve relevant genetic context, while engineered models can isolate a mechanism and improve experimental consistency.

Patient Derived Motor Neurons and Matched Controls

Motor neuron model qualification can include cell-line identity, genotype confirmation, genomic quality where appropriate, mycoplasma status, differentiation consistency, neuronal viability, and motor neuron marker expression. Markers such as ISL1, HB9, and ChAT are interpreted alongside morphology and functional maturation. A high marker-positive fraction does not by itself establish the disease phenotype needed for a screen.

An isogenic corrected line can help separate a particular genetic lesion from donor background, but clone-specific effects and editing quality still require attention. Unrelated healthy controls and independent differentiations provide complementary evidence. For sporadic ALS, a donor panel is designed to examine reproducibility and response variation; a phenotype in one line is treated as a line-specific observation until it is supported more broadly. Reprogramming-associated loss of age features is considered when selecting culture duration or additional stress paradigms.

Glial Contributions and Motor Neuron Support

Astrocyte and microglial components can be introduced when the hypothesis concerns inflammatory signaling, metabolic support, glutamate handling, or other non-cell-autonomous effects. Crossed co-cultures can compare disease and control neurons with disease and control glia to locate the origin of an injury or rescue signal. Cell proportions, activation conditions, and treatment exposure are controlled so that a change in neuronal survival is not simply attributed to a shift in culture composition.

Neuromuscular Junctions and Regional Three Dimensional Models

Motor neuron–skeletal muscle co-cultures provide a route to investigate axon extension, synaptic organization, denervation, and muscle responses. Structural association of presynaptic and postsynaptic markers is distinguished from evidence of functional neurotransmission. Where function is central, experiments can compare neuron-evoked muscle responses with direct muscle stimulation and suitable transmission controls, helping separate an NMJ effect from a direct action on muscle.

Selected programs can extend through our Neuromuscular Organoid Modeling Service or Neurodegeneration Organoid Modeling Service. More complex systems are introduced when multicellular organization, spatial exposure, or longer-term pathology materially changes the answer. Lower motor neuron systems are not assumed to represent upper motor neuron degeneration or the entire corticospinal circuit.

Connect Molecular Pathology with Motor Neuron Function

The assay panel should distinguish target engagement, correction of a disease-associated process, and recovery of cell function. These are related but separate observations. A compound may reduce an aggregate signal without improving neuronal survival, or improve a stress endpoint through a mechanism unrelated to the intended target. We define a primary endpoint and a small set of supporting measurements before expanding into exploratory profiling.

TDP 43 FUS and SOD1 Pathology

The TDP-43, FUS, SOD1 Localization & Aggregation Assay Service can support targeted imaging and biochemical evaluation. Nuclear depletion, cytoplasmic accumulation, phosphorylation, and detergent insolubility are assessed as distinct features when relevant. Their presence and relationship to injury must be established in the selected model before they become screening endpoints.

TDP-43 pathology is important in many ALS contexts, but it should not be imposed as a required phenotype in every SOD1- or FUS-associated model. Likewise, lowering total TDP-43 is not automatically beneficial because normal nuclear TDP-43 has essential RNA-regulatory functions. A TDP-43-focused study can pair pathological localization or aggregation with a qualified functional RNA readout and neuronal health measurements.

C9orf72 RNA and Dipeptide Repeat Biology

For repeat-expansion programs, the C9orf72 RNA Foci Formation Assay Service can be incorporated into a broader mechanistic package. Sense and antisense transcripts, RNA foci, selected dipeptide repeat proteins, endogenous C9orf72 expression, and cellular function may respond differently to an intervention. The detection reagents and relevant species are therefore specified in advance. Results do not assume that one DPR measurement captures the entire repeat-associated disease process.

Survival Excitability and Axonal Integrity

Longitudinal imaging can follow the same culture over time to separate early neurite changes from later cell loss. Absolute cell counts, motor neuron identity, apoptosis-related measures, and reporter-independent confirmation can strengthen interpretation. For electrophysiology, both increased and decreased activity may be meaningful depending on cell maturity, genotype, and the stage of degeneration. Suppressing firing is not described as functional rescue unless it restores a predefined abnormal phenotype within a tolerable range.

Screen Candidates in a Qualified Disease Window

Establish Assay Performance Before Screening

Feasibility studies evaluate baseline variability, the magnitude and timing of the disease-associated phenotype, vehicle tolerance, and compatibility between the candidate and readout. Reference compounds or genetic perturbations are selected for the endpoint they can meaningfully benchmark. A reference response is an experimental comparator rather than a promise that the model predicts clinical benefit. Acceptance criteria can include control separation, viability, technical variability, and repeatability across independent preparations.

Measure Concentration Response and Treatment Timing

Screening can use an initial concentration range or a staged primary and confirmation design, depending on material availability and program maturity. Hits are followed with concentration-response studies, time courses, and matched viability counterassays. Pretreatment, treatment at phenotype emergence, and rescue after established injury answer different questions and are reported separately. Delayed treatment may provide a stricter test of rescue, but only if a measurable and intervention-sensitive phenotype remains.

Potency estimates are reported with the cell model, exposure duration, endpoint, normalization, and fitting convention. Curves that do not cover a sufficiently broad response range are identified as incomplete rather than assigned an unsupported EC50. Maximum observed rescue is considered alongside tolerability and the initial disease deficit. An endpoint that improves beyond the healthy-control range is examined for altered proliferation, cell composition, reporter behavior, or nonspecific stimulation.

Confirm Hits Across Methods and Biological Replicates

A primary imaging hit can be confirmed with an independent protein, survival, or functional assay that has different sources of bias. Fluorescent compounds, metabolic modulators, and agents affecting reporter expression require appropriate interference checks. Candidate ranking can combine reproducibility, effect size, concentration dependence, cellular exposure, and the mechanistic fit. A single favorable endpoint does not outweigh evidence of toxicity or loss of motor neuron identity.

Technical wells are distinguished from independent differentiations, clones, and donors. Where donor variation is part of the research question, analyses retain donor-level responses and avoid treating every well as an independent patient. Study plans can include blinded image analysis, randomized plate allocation, predefined exclusions, and suitable batch modeling. The number of donors and repeats is selected for the effect and decision of interest rather than presented as a universal fixed package.

Projects focused on cellular rescue can connect with our Motor Neuron related Phenotypic Screening Assay Service. This route can combine motor neuron morphology and survival with selected molecular and electrophysiological endpoints, allowing a screening signal to be tested against the biological outcome the program aims to improve.

Related Research

Patient Derived Motor Neurons Support Longitudinal Rescue Studies

Bye and colleagues established a sporadic ALS iPSC resource and evaluated motor neuron phenotypes and drug responses across donors. Their longitudinal framework connected neurite measurements with survival-related outcomes and pharmacological testing. The selected images compare vehicle and riluzole-treated cultures from several donors, illustrating why lead confirmation should retain donor-level information and pair morphology with independent health measurements.

Fig. 1 Representative motor neuron cultures from eight sporadic ALS donors under vehicle or riluzole treatment.^1,3

Neuromuscular Co Cultures Help Localize ALS Cytopathy

Ting and colleagues developed a human iPSC-derived neuromuscular junction model using cryopreserved motor neurons and skeletal myoblasts. Cross-culture experiments with SOD1 mutant and control components investigated the contribution of the neuronal compartment to neuromuscular abnormalities. The schematic summarizes the research model and its ALS application.

Fig. 2 Published human iPSC-derived NMJ modeling framework and its application to ALS research.^2,3

Frequently Asked Questions

1. What does the ALS drug discovery service include?

   Projects can combine model selection and qualification, motor neuron phenotypic screening, molecular and functional assays, mechanism-of-action studies, and selected preclinical confirmation. The scope follows the therapeutic hypothesis, candidate modality, disease context, and the development decision the data must support.

2. Can you support familial and sporadic ALS studies?

   Yes. Genotype-focused studies can address SOD1, TARDBP, FUS, or C9orf72 contexts, while sporadic ALS programs can use qualified patient-derived models and donor panels. Model availability, controls, disease phenotype, and the need for independent lines are assessed during project design.

3. How do you choose an ALS model for a candidate?

   We match the model to the intended target, genotype, cell population, delivery requirements, and measurable disease phenotype. Engineered lines, patient-derived motor neurons, glial co-cultures, neuromuscular systems, and animal models answer different questions; no single model is assumed to represent all ALS biology.

4. Which endpoints can be used for ALS compound screening?

   Endpoints can include motor neuron survival, neurite integrity, protein localization and aggregation, RNA foci, selected dipeptide repeat proteins, RNA-processing defects, mitochondrial or inflammatory signals, electrophysiology, and neuromuscular function. The primary endpoint must first be qualified in the chosen model.

5. Can the service evaluate oligonucleotides or gene-delivered candidates?

   Such projects can be assessed for feasibility and configured with modality-appropriate delivery controls, target modulation, tolerability, and functional confirmation. Sequence compatibility, cell-type access, expression or knockdown, and durability are considered. Specialized delivery and model requirements are agreed before implementation.

6. How do you distinguish neuroprotection from an assay artifact?

   We combine concentration-response testing with viable cell counts, motor neuron identity, independent readouts, and controls for reporter or detection interference. Longitudinal and orthogonal measurements help distinguish cell preservation from altered metabolism, neurite growth, fluorescence, or changes in culture composition.

7. Can ALS studies include neuromuscular junction or animal models?

   Selected programs can add motor neuron–muscle systems, neuromuscular organoids, or suitable ALS animal models. These stages are planned around the biological claim, exposure needs, and available models. Structural NMJ markers, functional transmission, and direct muscle effects are evaluated separately where relevant.

8. What information is useful when starting an ALS discovery project?

   Useful inputs include the ALS genotype or donor context, intended mechanism, candidate modality and material availability, preferred models, delivery needs, primary endpoint, treatment timing, and advancement criteria. A feasibility phase can define the disease window and screening strategy when these elements remain open.

Discuss Your ALS Drug Discovery Project

Share the ALS subtype or molecular mechanism, candidate class, intended cell population, available material, and the decision your team needs to make. Creative Biolabs can help select a suitable model, establish meaningful controls, and connect target-related changes with motor neuron or neuromuscular outcomes. Assay scope, feasibility, study stages, and reporting expectations are defined before execution.

References

1. Bye, Christopher R., et al. "Large-Scale Drug Screening in iPSC-Derived Motor Neurons from Sporadic ALS Patients Identifies a Potential Combinatorial Therapy." Nature Neuroscience, vol. 29, 2026, pp. 40-52. https://doi.org/10.1038/s41593-025-02118-7
2. Ting, Hsiao-Chien, et al. "Rapid iPSC-Derived Neuromuscular Junction Model Uncovers Motor Neuron Dominance in Amyotrophic Lateral Sclerosis Cytopathy." Cell Death Discovery, vol. 11, 2025, article 23. https://doi.org/10.1038/s41420-025-02302-5
3. Distributed under Open Access license CC BY 4.0, without modification.